FTSE MIB
33.308,77 -366,38 (-1,09%) Dow Jones
39.150,33 +15,57 (+0,04%) Nasdaq
17.689,36 -32,23 (-0,18%) Nikkei 225
38.596,47 -36,55 (-0,09%) Petrolio
82,34 +0,17 (+0,21%) Bitcoin EUR
60.223,37 +144,60 (+0,24%)
Context Therapeutics Inc. (CNTX)
Dopo ore:
| Chiusura precedente | 2,1700 |
| Aperto | 2,1700 |
| Denaro | 2,1000 x 500 |
| Domanda | 2,2100 x 200 |
| Min-Max giorno | 1,9501 - 2,2300 |
| Intervallo di 52 settimane | 0,7700 - 2,2400 |
| Volume | |
| Media Volume | 698.546 |
| Capitalizzazione | 161,996M |
| Beta (mensile su 5 anni) | 2,32 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,40 |
GlobeNewswireContext Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA. Details of the presenta
- GlobeNewswire
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming
- GlobeNewswire
Context Therapeutics to Participate in Two August 2023 Investor Conferences
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023. Details of the events are as follows: BTIG Virtual Biotechnology Conference 2023: Context CEO Martin Lehr will participate in a fireside chat taking place on Mo
